Osteosarcoma
Conditions
Interventions
Intervention group:combining realgar-Indigo naturalis formula and Cisplatin
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
6 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Age 6-70 years old 2) Osteosarcoma patients who have failed standard treatments. Standard treatment failure is defined as tumor progression, recurrence or metastasis during or after the end of chemotherapy using first-line chemotherapy drugs (including high-dose methotrexate, doxorubicin, cisplatin, ifosfamide, etc.). 3) Imaging shows recurrence, enlargement of metastases or new metastases with a maximum diameter of =5 mm, and two consecutive CT scans (one month apart) confirm the presence of nodules, or puncture confirms metastases. 4) Understand the entire process of this study, voluntarily participate and sign the informed consent form. For subjects who cannot understand the informed consent form or cannot accurately express their wishes, their legal representative can sign the informed consent form and have the subject's fingerprint.
Exclusion criteria
Exclusion criteria: 1) Patients with incomplete data on previous diagnosis and treatment, or pathological white films of the primary tumor focus are unavailable 2) Patients with ECOG=3 points and cardiopulmonary function assessment results who cannot tolerate the expected treatment 3) Patients with serious heart, liver, kidney diseases, pregnant or lactating patients 4) Uncorrectable bleeding tendency or coagulation disorder 5) There is systemic infection or puncture site infection 6) The subject refused to join this study and had poor compliance. 7) According to the researcher's judgment, the patient may have other factors that may cause the study to be terminated midway, such as other serious diseases or serious laboratory abnormalities or other conditions that may affect the safety of the subjects or the trial data and factors such as family or society where samples were collected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate, ORR;Overall survival, OS;AER; | — |
Countries
China
Contacts
Public ContactJunqiang Yin
The First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed